Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies
Cryoport, a leader in life sciences supply chain solutions, and Minaris Regenerative Medicine, a contract development and manufacturing organization, announced a strategic partnership on June 20, 2024. This collaboration aims to provide fully integrated logistics and manufacturing services for regenerative medicine products, supporting the advancement of cell and gene therapies. Combining Cryoport's logistics expertise with Minaris' manufacturing capabilities, the partnership will offer comprehensive services from cell and tissue collection to delivery, ensuring secure transport and quality assurance. The partnership will initially focus on Minaris' Japan-based branch but plans to extend services across the entire Minaris group.
- Strategic partnership announced between Cryoport and Minaris Regenerative Medicine.
- Collaboration to provide fully integrated logistics and manufacturing services for regenerative medicine products.
- Combination of Cryoport's logistics expertise and Minaris' manufacturing capabilities.
- Partnership to support the advancement of cell and gene therapies.
- Focus on secure transport and quality assurance for regenerative medicine products.
- None.
Insights
The partnership between Cryoport and Minaris aims to provide end-to-end logistics and manufacturing services for the cell and gene therapy market. This collaboration could be highly beneficial for both companies in various ways.
Cryoport, known for its cold chain logistics solutions, expands its reach and service offerings through Minaris' established expertise in manufacturing regenerative medicine products. This enhances Cryoport's value proposition and could drive revenue growth in the long term. Additionally, integrating logistics and manufacturing services under one roof can streamline operations and reduce costs, improving overall efficiency and margins.
Minaris benefits by leveraging Cryoport’s logistics capabilities, ensuring that their high-quality manufactured products are delivered safely and timely. This partnership might allow Minaris to focus more on their core competencies in manufacturing, potentially increasing their production capacity and customer satisfaction.
For investors, the collaboration signifies both companies' commitment to strengthening their market positions in a rapidly growing industry. However, it's important to monitor how this partnership impacts their financials over time, especially regarding integration costs and operational synergies.
This partnership addresses a critical need in the cell and gene therapy sector: the secure and efficient transportation and manufacturing of sensitive biological materials.
Regenerative medicine products, such as stem cells and engineered tissues, require precise handling and storage conditions to maintain their viability. Cryoport's expertise in cold chain logistics will be important in ensuring these products are transported at the correct temperatures, minimizing the risk of degradation. This reliability could enhance the success rates of therapies reaching patients in optimal condition.
From a research and development perspective, having a streamlined supply chain and manufacturing process can accelerate the time-to-market for new therapies. This collaboration might also foster innovation, as companies can focus more on developing advanced treatments rather than logistics and manufacturing challenges.
In summary, this partnership could be transformative for the regenerative medicine field, potentially leading to faster and more reliable delivery of new therapies to patients.
Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products
The collaboration combines Cryoport's extensive capabilities and experience in meeting the logistics needs of the life sciences industry and Minaris' expertise in contract manufacturing of regenerative medicine products including stem cells, gene therapy, biomaterials and engineered tissue.
Jerrell Shelton, CEO of Cryoport, commented, "We look forward to partnering with Minaris to provide cohesive supply chain solutions and manufacturing services for regenerative medicine products, starting from the collection of cells and tissues all the way to the delivery of these critical products and services to patients. This partnership perfectly aligns with our organization's commitment to support the medical community and the people it serves."
Dr. Hiroto Bando, CEO of Minaris, added, "Ensuring secure transport, including the use and operation of specialized containers, as well as quality assurance, is essential for regenerative medicine products. By partnering with Cryoport, a best-in-class company that has considerable resources in all these areas, we will collaborate to provide high-quality services tailored to the exact needs of our customers. While this partnership is with Minaris'
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for cell & gene therapies that enable manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Its corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
About Minaris Regenerative Medicine Co., Ltd.
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. Our vision is creating future cell therapy miracles together and we are committed to providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society's well-being. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 25 years' experience providing outstanding quality and reliability. Our facilities in
For more information about Minaris, please visit https://www.rm.minaris.com/en/
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport's anticipation that its revenue will progressively improve throughout the year, including anticipated acceleration of revenue from the Cryoport's Cell & Gene Therapy clients, Cryoport's expectations that MVE's cryogenic system sales will be challenged throughout the remainder of the year, the Cryoport's expectations of the long-term prospects of its Life Sciences Products business, including the anticipation of demand normalizing, which would allow Cryoport to benefit from its position as the global leader in this space, and Cryoport's planned initiatives to drive toward positive adjusted EBITDA and cash flow in the near term, which it expects should positively impact its results of operations for the second half of 2024. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-and-minaris-regenerative-medicine-form-strategic-partnership-to-support-advancement-of-cell-and-gene-therapies-302177700.html
SOURCE Cryoport, Inc.
FAQ
What is the strategic partnership between Cryoport and Minaris Regenerative Medicine about?
When was the partnership between Cryoport and Minaris Regenerative Medicine announced?
What are Cryoport's roles in the partnership with Minaris Regenerative Medicine?
What are Minaris Regenerative Medicine's contributions to the partnership with Cryoport?
What is the stock symbol of Cryoport?
